Context
BioNTech is a German one stop shop immuno-oncology company with a full spectrum of technologies to tackle cancer, which differentiates it from other mRNA and immuno-oncology companies.
The company’s mRNA-based platform serves as a foundation on which it can build multiple treatment modalities, including cancer vaccines FixVac, based on a fixed combination of shared cancer antigens, and iNeST for patient-specific cancer antigen therapy.
In March 2020 the company leveraged its mRNA platform and its infectious diseases partnership with Pfizer by expanding its pipeline to Covid-19, and in this context signed an additional partnership with Fosun. In July 2020, BioNTech and Pfizer signed multiple supply agreements for Covid 19 vaccine with the UK and US governments.
BioNTech has developed industry-leading collaborations across all pipeline with Pfizer, Fosun Genmab, Genentech, Sanofi…
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma and Pfizer.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Co-manager to BioNTech on its USD511.5 million upsized Publicly-marketed Follow-on Offering
Bryan, Garnier & Co acted as Co-manager on the BioNTech’s inaugural follow-on. In October 2019, we worked with BioNTech during its Nasdaq IPO.
BioNTech raised USD511.5m in an upsized fully SEC-registered global underwritten offering of ADSs.
Following a two-day fully marketed book-building process, the offering priced at $93 per ADS, representing a discount of 10.7% on the closing price and a premium of 5.4% on the price before the offering’s launch. This also represents a premium of 520% to the IPO offer price.
Bryan, Garnier & Co brought international demand in the book including Tier-1 healthcare specialists in this multiple times oversubscribed transaction.
Following the Underwritten Offering, BioNTech announced the launch of an international Rights Offering to subscribe up to 2.0m shares of the company, leading to a unique and unprecedented deal structure for Nasdaq-listed biotech.
This transaction underlines the commitment, knowledge and belief of Bryan, Garnier & Co in mRNA platforms after our work with both Moderna and BioNTech.
Share